Stevanato Group S.p.A. $STVN is Cooper Investors PTY Ltd.’s 5th Largest Position

Cooper Investors PTY Ltd. raised its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN) by 17.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 695,245 shares of the company’s stock after acquiring an additional 104,937 shares during the quarter. Stevanato Group makes up about 4.6% of Cooper Investors PTY Ltd.’s investment portfolio, making the stock its 5th biggest position. Cooper Investors PTY Ltd.’s holdings in Stevanato Group were worth $13,988,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Royal Bank of Canada boosted its stake in shares of Stevanato Group by 10.8% in the first quarter. Royal Bank of Canada now owns 437,284 shares of the company’s stock worth $8,930,000 after acquiring an additional 42,731 shares during the period. Russell Investments Group Ltd. lifted its holdings in Stevanato Group by 108.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 191,103 shares of the company’s stock worth $4,669,000 after purchasing an additional 99,408 shares in the last quarter. Loomis Sayles & Co. L P bought a new position in Stevanato Group in the 2nd quarter worth approximately $13,729,000. New York State Common Retirement Fund boosted its stake in Stevanato Group by 2.5% in the 2nd quarter. New York State Common Retirement Fund now owns 417,736 shares of the company’s stock worth $10,205,000 after purchasing an additional 10,277 shares during the period. Finally, Sei Investments Co. grew its holdings in Stevanato Group by 16.9% during the 2nd quarter. Sei Investments Co. now owns 231,244 shares of the company’s stock valued at $5,649,000 after buying an additional 33,419 shares in the last quarter.

Stevanato Group Stock Down 0.2%

NYSE STVN opened at €13.40 on Monday. The stock has a 50 day moving average price of €15.79 and a 200-day moving average price of €20.73. Stevanato Group S.p.A. has a one year low of €12.89 and a one year high of €28.00. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.26 and a current ratio of 1.76. The company has a market capitalization of $4.06 billion, a P/E ratio of 23.10, a P/E/G ratio of 1.20 and a beta of 0.57.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on STVN. KeyCorp lowered their target price on shares of Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Weiss Ratings downgraded shares of Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 11th. Wall Street Zen cut shares of Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Morgan Stanley dropped their price objective on shares of Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a report on Friday, March 6th. Finally, Jefferies Financial Group set a $17.50 target price on Stevanato Group in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Stevanato Group presently has an average rating of “Moderate Buy”.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.